Journal of Clinical Endocrinology & Metabolism, Vol 74, 934-938, Copyright © 1992 by Endocrine Society

ARTICLES

Diminished growth hormone-binding protein in children with insulin- dependent diabetes mellitus

RK Menon, S Arslanian, B May, WS Cutfield and MA Sperling
Division of Endocrinology, Children's Hospital of Pittsburgh, Pennsylvania 15213.

Two distinct GH-binding proteins (GHBP) are present in circulation in the human. The major GHBP (high affinity GHBP) is homologous to the extracellular portion of the GH receptor and the concentration of this protein in circulation may reflect the status of the GH receptor in the tissues. To gain information about the concentration of GHBPs in children with insulin-dependent diabetes mellitus (IDDM), we measured GHBP in the serum of 46 children with IDDM and compared it to that in 53 healthy control subjects matched for age and sexual maturity. The total GHBP concentration in the group of pubertal and postpubertal IDDM patients was lower than that measured in the control group (mean +/- SEM: 7.8 +/- 0.4 vs. 9.0 +/- 0.5%, P = 0.05). The diabetic children in stages II to IV of puberty had a lower GHBP level compared to their healthy controls (7.6 +/- 0.4 vs. 9.1 +/- 0.5%, P = 0.02), whereas the difference between the diabetic and control group of postpubertal children was not statistically different (8.3 +/- 0.7 vs. 9.7 +/- 0.7%, P = 0.1). In a randomly selected subset of eight patients and eight controls, the concentration of the individual GHBPs (i.e. high affinity and low affinity (GHBP) was estimated by gel chromatography. There was no difference in the low affinity GHBP between the two groups (9.9 +/- 0.6% vs. 9.9 +/- 0.4%), but the high affinity GHBP was less in the diabetic group than in the control group (10.5 +/- 0.9 vs. 15.6 +/- 1.0%, P less than 0.01). In the diabetic group, there was no correlation between the GHBP levels and age, duration of diabetes, hemoglobin A1, or insulin dose. We conclude that in IDDM there is less of the high affinity GHBP, suggesting a decrease in the number of GH receptors in these patients. This decrease may contribute to GH resistance manifesting as decreased insulin-like growth factor-I levels despite high GH levels in patients with IDDM.

This article has been cited by other articles:

				K. Ekstrom, J. Salemyr, I. Zachrisson, C. Carlsson-Skwirut, E. Ortqvist, and P. Bang Normalization of the IGF-IGFBP Axis by Sustained Nightly Insulinization in Type 1 Diabetes Diabetes Care, June 1, 2007; 30(6): 1357 - 1363. [Abstract] [Full Text] [PDF]

				J. Thimmarayappa, J. Sun, L. E. Schultz, P. Dejkhamron, C. Lu, A. Giallongo, J. L. Merchant, and R. K. Menon Inhibition of Growth Hormone Receptor Gene Expression by Saturated Fatty Acids: Role of Kruppel-Like Zinc Finger Factor, ZBP-89 Mol. Endocrinol., November 1, 2006; 20(11): 2747 - 2760. [Abstract] [Full Text] [PDF]

				J. Xu, Z. Liu, T. L. Clemens, and J. L. Messina Insulin Reverses Growth Hormone-induced Homologous Desensitization J. Biol. Chem., August 4, 2006; 281(31): 21594 - 21606. [Abstract] [Full Text] [PDF]

				J. Xu, A. B. Keeton, J. L. Franklin, X. Li, D. Y. Venable, S. J. Frank, and J. L. Messina Insulin Enhances Growth Hormone Induction of the MEK/ERK Signaling Pathway J. Biol. Chem., January 13, 2006; 281(2): 982 - 992. [Abstract] [Full Text] [PDF]

				P. M. Gowri, J. H. Yu, A. Shaufl, M. A. Sperling, and R. K. Menon Recruitment of a Repressosome Complex at the Growth Hormone Receptor Promoter and Its Potential Role in Diabetic Nephropathy Mol. Cell. Biol., February 1, 2003; 23(3): 815 - 825. [Abstract] [Full Text]

				S. Ji, R. Guan, S. J. Frank, and J. L. Messina Insulin Inhibits Growth Hormone Signaling via the Growth Hormone Receptor/JAK2/STAT5B Pathway J. Biol. Chem., May 7, 1999; 274(19): 13434 - 13442. [Abstract] [Full Text] [PDF]

				B. Tonshoff, M. J. Cronin, M. Reichert, D. Haffner, A.-M. Wingen, W. F. Blum, and O. Mehls Reduced Concentration of Serum Growth Hormone (GH)-Binding Protein in Children with Chronic Renal Failure: Correlation with GH Insensitivity J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1007 - 1013. [Abstract] [Full Text] [PDF]

				K. Thrailkill, T. Quattrin, L. Baker, J. Litton, K. Dwigun, M. Rearson, M. Poppenheimer, D. Kotlovker, D. Giltinan, N. Gesundheit, et al. Dual Hormonal Replacement Therapy with Insulin and Recombinant Human Insulin-Like Growth Factor (IGF)-I in Insulin-Dependent Diabetes Mellitus: Effects on the Growth Hormone/IGF/IGF-Binding Protein System J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1181 - 1187. [Abstract] [Full Text] [PDF]

				S. Fisker, N. Vahl, J. O. L. Jorgensen, J. S. Christiansen, and H. Orskov Abdominal Fat Determines Growth Hormone-Binding Protein Levels in Healthy Nonobese Adults J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 123 - 128. [Abstract] [Full Text] [PDF]